185 related articles for article (PubMed ID: 36935177)
1. Clinical and immunological characteristics of PD-1 associated fulminant type 1 diabetes mellitus.
Qiu J; Luo S; Yin W; Li X; Zhou Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Jan; 48(1):49-58. PubMed ID: 36935177
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
[TBL] [Abstract][Full Text] [Related]
3. Type 1 diabetes mellitus induced by PD-1 inhibitors in China: a report of two cases.
Luo J; Feng J; Liu C; Yang Z; Zhan D; Wu Y; Pan L; Zhang L
J Int Med Res; 2022 Sep; 50(9):3000605221121940. PubMed ID: 36171723
[TBL] [Abstract][Full Text] [Related]
4. [Clinical characteristics of immune checkpoint inhibitor-related type 1 diabetes mellitus].
Qiu JL; Luo SM; Yin WF; Li X; Zhou ZG
Zhonghua Yi Xue Za Zhi; 2023 Jan; 103(1):38-41. PubMed ID: 36594136
[TBL] [Abstract][Full Text] [Related]
5. Characterization of immune checkpoint inhibitor-associated fulminant type 1 diabetes associated with autoantibody status and ethnic origin.
Qiu J; Luo S; Yin W; Guo K; Xiang Y; Li X; Liu Z; Zhou Z
Front Immunol; 2022; 13():968798. PubMed ID: 36451831
[TBL] [Abstract][Full Text] [Related]
6. Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype.
Marchand L; Thivolet A; Dalle S; Chikh K; Reffet S; Vouillarmet J; Fabien N; Cugnet-Anceau C; Thivolet C
Acta Diabetol; 2019 Apr; 56(4):441-448. PubMed ID: 30284618
[TBL] [Abstract][Full Text] [Related]
7. Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab.
Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2018 Jan; 244(1):33-40. PubMed ID: 29343652
[TBL] [Abstract][Full Text] [Related]
8. Clinical and HLA genotype analysis of immune checkpoint inhibitor-associated diabetes mellitus: a single-center case series from China.
Liu YC; Liu H; Zhao SL; Chen K; Jin P
Front Immunol; 2023; 14():1164120. PubMed ID: 37359544
[TBL] [Abstract][Full Text] [Related]
9. Type 1 diabetes related to immune checkpoint inhibitors.
Tachibana M; Imagawa A
Best Pract Res Clin Endocrinol Metab; 2022 May; 36(3):101657. PubMed ID: 35450793
[TBL] [Abstract][Full Text] [Related]
10. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
Wen L; Zou X; Chen Y; Bai X; Liang T
Front Immunol; 2020; 11():2076. PubMed ID: 32973816
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event.
Yilmaz M
J Oncol Pharm Pract; 2020 Jan; 26(1):236-239. PubMed ID: 30955467
[TBL] [Abstract][Full Text] [Related]
12. Efficacies of programmed cell death 1 ligand 1 blockade in non-small cell lung cancer patients with acquired resistance to prior programmed cell death 1 inhibitor and development of diabetic ketoacidosis caused by two different etiologies: a retrospective case series.
Ishi A; Tanaka I; Iwama S; Sakakibara T; Mastui T; Kobayashi T; Hase T; Morise M; Sato M; Arima H; Hashimoto N
Endocr J; 2021 May; 68(5):613-620. PubMed ID: 33790087
[TBL] [Abstract][Full Text] [Related]
13. PD-1 inhibitor-associated type 1 diabetes: A case report and systematic review.
Lin C; Li X; Qiu Y; Chen Z; Liu J
Front Public Health; 2022; 10():885001. PubMed ID: 35991054
[TBL] [Abstract][Full Text] [Related]
14. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
Yaura K; Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2021 Aug; 254(4):253-256. PubMed ID: 34373422
[TBL] [Abstract][Full Text] [Related]
15. [Clinical and immunological characteristics in rapid-onset type 1 diabetes with hyperamylasemia].
Zhang C; Zhou ZG; Zhang DM; Yang XL; Zhou M; Lin J; Huang G; Wang JP
Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):967-71. PubMed ID: 16061004
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes.
Kotwal A; Haddox C; Block M; Kudva YC
BMJ Open Diabetes Res Care; 2019; 7(1):e000591. PubMed ID: 30899528
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes.
Miyoshi Y; Ogawa O; Oyama Y
Tohoku J Exp Med; 2016 Jun; 239(2):155-8. PubMed ID: 27297738
[TBL] [Abstract][Full Text] [Related]
18. Acute-onset diabetes mellitus with ketoacidosis in a nivolumab-treated patient with hepatocellular carcinoma.
Harsch IA; Konturek PC
Wiad Lek; 2018; 71(5):945-948. PubMed ID: 30176620
[TBL] [Abstract][Full Text] [Related]
19. Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.
Clotman K; Janssens K; Specenier P; Weets I; De Block CEM
J Clin Endocrinol Metab; 2018 Sep; 103(9):3144-3154. PubMed ID: 29955867
[TBL] [Abstract][Full Text] [Related]
20. New onset diabetes with ketoacidosis following nivolumab immunotherapy: A case report and review of literature.
Delasos L; Bazewicz C; Sliwinska A; Lia NL; Vredenburgh J
J Oncol Pharm Pract; 2021 Apr; 27(3):716-721. PubMed ID: 32723064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
